<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Thalidomide is an effective treatment for recurrent <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> but its effectiveness at low dose has been rarely assessed </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Single-centre non-randomized retrospective open study </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Forty-seven patients were treated with thalidomide for recurrent <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> (41 patients) or <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et disease (six patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Remission was obtained with a dose of 25 mg daily </plain></SENT>
<SENT sid="4" pm="."><plain>Discontinuation of treatment for side effects was not observed in this case series </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> </plain></SENT>
</text></document>